Literature DB >> 11699843

Update: Investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy, October 2001.

.   

Abstract

Since October 3, 2001, CDC and state and local public health authorities have been investigating cases of bioterrorism-related anthrax. This report updates previous findings, provides new information on case investigations in two additional areas, presents the susceptibility patterns of Bacillus anthracis isolates, and provides interim recommendations for managing potential threats and exposures and for treating anthrax.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11699843

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN： 0149-2195            Impact factor:   17.586


  56 in total

Review 1.  Biological warfare and bioterrorism.

Authors:  Nicholas J Beeching; David A B Dance; Alastair R O Miller; Robert C Spencer
Journal:  BMJ       Date:  2002-02-09

2.  Inhalational anthrax: radiologic and pathologic findings in two cases.

Authors:  Bradford J Wood; Bryan DeFranco; Mary Ripple; Martin Topiel; Carlos Chiriboga; Venkat Mani; Kevin Barry; Dave Fowler; Henry Masur; Luciana Borio
Journal:  AJR Am J Roentgenol       Date:  2003-10       Impact factor: 3.959

3.  Efficacy of Daptomycin against Bacillus anthracis in a murine model of anthrax spore inhalation.

Authors:  Henry S Heine; Jennifer Bassett; Lynda Miller; Bret K Purcell; W Russell Byrne
Journal:  Antimicrob Agents Chemother       Date:  2010-07-19       Impact factor: 5.191

4.  Antibiotic susceptibility and molecular diversity of Bacillus anthracis strains in Chad: detection of a new phylogenetic subgroup.

Authors:  Angaya Maho; Alexandra Rossano; Herbert Hächler; Anita Holzer; Esther Schelling; Jakob Zinsstag; Mahamat H Hassane; Bhen S Toguebaye; Ayayi J Akakpo; Matthew Van Ert; Paul Keim; Leo Kenefic; Joachim Frey; Vincent Perreten
Journal:  J Clin Microbiol       Date:  2006-09       Impact factor: 5.948

5.  Anthrax: a continuing concern in the era of bioterrorism.

Authors:  Stefan Riedel
Journal:  Proc (Bayl Univ Med Cent)       Date:  2005-07

6.  Pharmacokinetics-pharmacodynamics of gatifloxacin in a lethal murine Bacillus anthracis inhalation infection model.

Authors:  Paul G Ambrose; Alan Forrest; William A Craig; Chistopher M Rubino; Sujata M Bhavnani; George L Drusano; Henry S Heine
Journal:  Antimicrob Agents Chemother       Date:  2007-09-17       Impact factor: 5.191

7.  Beta-lactamase genes of the penicillin-susceptible Bacillus anthracis Sterne strain.

Authors:  Yahua Chen; Janice Succi; Fred C Tenover; Theresa M Koehler
Journal:  J Bacteriol       Date:  2003-02       Impact factor: 3.490

8.  Use of an in vitro pharmacodynamic model to derive a linezolid regimen that optimizes bacterial kill and prevents emergence of resistance in Bacillus anthracis.

Authors:  A Louie; H S Heine; K Kim; D L Brown; B VanScoy; W Liu; M Kinzig-Schippers; F Sörgel; G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2008-05-05       Impact factor: 5.191

9.  MICs of selected antibiotics for Bacillus anthracis, Bacillus cereus, Bacillus thuringiensis, and Bacillus mycoides from a range of clinical and environmental sources as determined by the Etest.

Authors:  Peter C B Turnbull; Nicky M Sirianni; Carlos I LeBron; Marian N Samaan; Felicia N Sutton; Anatalio E Reyes; Leonard F Peruski
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

10.  Opening a bacillus anthracis-containing envelope, Capitol Hill, Washington, D.C.: the public health response.

Authors:  Vincent P Hsu; Susan L Lukacs; Thomas Handzel; James Hayslett; Scott Harper; Thomas Hales; Vera A Semenova; Sandra Romero-Steiner; Cheryl Elie; Conrad P Quinn; Rima Khabbaz; Ali S Khan; Gregory Martin; John Eisold; Anne Schuchat; Rana A Hajjeh
Journal:  Emerg Infect Dis       Date:  2002-10       Impact factor: 6.883
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.